ATHOS KG
Overview
ATHOS KG is the single family office of the German entrepreneurial family Strüngmann, specifically brothers Andreas and Thomas Strüngmann who founded the generic drug manufacturer Hexal. It functions as a long-term, value-based investor with a primary focus on healthcare, life sciences, biotechnology, and technology-driven companies. The firm is known for its significant and foundational investment in BioNTech, the company that developed a widely used COVID-19 vaccine.
Portfolio Companies
4
Website
athos.deInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Doctolib | Apr 2026 | Secondary | Co-investor |
| Bactolife | Jan 2026 | Series B | Co-investor |
| AMSilk | May 2021 | Series C | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is ATHOS KG based?
ATHOS KG is headquartered in Holzkirchen, Bavaria, Germany.
When was ATHOS KG founded?
Founding year information for ATHOS KG is not publicly available.
How many portfolio companies does ATHOS KG have?
ATHOS KG has 4 portfolio companies in Caplight's dataset.
What are some companies in ATHOS KG's portfolio?
Portfolio companies visible on Caplight include Doctolib, Bactolife, AMSilk.
What was ATHOS KG's most recent investment shown here?
ATHOS KG's most recent investment in this portfolio sample was in Doctolib in 2026.
What sectors does ATHOS KG focus on?
ATHOS KG focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Enterprise Software, Healthcare & Life Sciences, Consumer & Commerce, Consumer & Commerce.
What company stages does ATHOS KG focus on?
ATHOS KG typically invests at the Mid stage.